

Yondelis[®] (trabectedin) (Intravenous)

Document Number: IC-0257

Last Review Date: 06/02/2020

Date of Origin: 12/04/2015

Dates Reviewed: 12/2015, 07/2016, 02/2017, 05/2017, 08/2017, 11/2017, 02/2018, 05/2018, 09/2018, 12/2018, 03/2019, 06/2019, 9/2019, 12/2019, 03/2020, 06/2020

I. Length of Authorization

Coverage will be provided for six months and may be renewed.

II. Dosing Limits

A. Quantity Limit (max daily dose) [NDC Unit]:

- 1 mg vial for injection: 4 vials every 21 days

B. Max Units (per dose and over time) [HCPCS Unit]:

- 40 billable units every 21 days

III. Initial Approval Criteria ^{1,2,3}

Coverage is provided in the following conditions:

- Patient is 18 years or older; **AND**

Universal Criteria ^{1,3}

- Left ventricular ejection fraction (LVEF) is within normal limits prior to initiating therapy and will be assessed at regular intervals during treatment; **AND**
- Must be used as single agent therapy; **AND**

Liposarcoma & Leiomyosarcoma (including uterine leiomyosarcoma) † Φ ^{1,3}

- Patient has unresectable, metastatic, or recurrent disease; **AND**
- Used as subsequent therapy after an anthracycline-containing regimen (e.g., doxorubicin, etc.)

Soft Tissue Sarcoma (STS) ‡ Φ ²

- Used as palliative therapy; **AND**
- Patient has a diagnosis of one of the following sub-types of soft tissue sarcoma:
 - Angiosarcoma; **AND**
 - Used as palliative therapy

- Rhabdomyosarcoma; **AND**
 - Used as palliative subsequent therapy for pleomorphic rhabdomyosarcoma; **OR**
 - Used as palliative therapy for non-pleomorphic rhabdomyosarcoma
- Retroperitoneal/Intra-abdominal; **AND**
 - Used as palliative subsequent therapy for recurrent unresectable or stage IV disease
- Extremity/Body Wall, Head/Neck; **AND**
 - Used as palliative subsequent therapy for advanced or metastatic disease with disseminated metastases
- Solitary Fibrous Tumor; **AND**
 - Used as palliative subsequent therapy
- Undifferentiated Pleomorphic Sarcoma; **AND**
 - Used as palliative therapy

† FDA approved indication(s); ‡ Compendia recommended indication(s); Φ Orphan Drug

IV. Renewal Criteria ¹

Authorizations can be renewed based on the following criteria:

- Patient continues to meet universal and other indication-specific relevant criteria such as concomitant therapy requirements (not including prerequisite therapy), performance status, etc. identified in section III; **AND**
- Disease response with treatment as defined by stabilization of disease or decrease in size of tumor or tumor spread; **AND**
- Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include: cardiomyopathy, rhabdomyolysis, hepatotoxicity and/or severe hepatic impairment, capillary leak syndrome (CPS), severe neutropenia/neutropenic sepsis, extravasation resulting in tissue necrosis, etc.; **AND**
- Left ventricular ejection fraction (LVEF) has not had an absolute decrease from baseline \geq 15% or is not below the lower limit of normal (LLN) with an absolute decrease of \geq 5%

V. Dosage/Administration

Indication	Dose
All indications	1.5 mg/m ² administered intravenously (IV) every 21 days, until disease progression or unacceptable toxicity

VI. Billing Code/Availability Information

HCPCS Code:

- J9352 - Injection, trabectedin, 0.1 mg: 1 billable unit = 0.1 mg

NDC:

- Yondelis 1 mg vial for injection: 59676-0610-xx

VII. References

1. Yondelis [package insert]. Horsham, PA; Janssen Products, LP; January 2019. Accessed April 2020.
2. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) trabectedin. National Comprehensive Cancer Network, 2020. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed April 2020.
3. Demetri GD, von Mehren M, Jones RL, et al. A randomized phase III study of trabectedin (T) or dacarbazine (D) for the treatment of patients (pts) with advanced liposarcoma (LPS) or leiomyosarcoma (LMS). Journal of Clinical Oncology 2015 33:15_suppl, 10503-10503
4. CGS Administrators, LLC. Local Coverage Article (LCA): Trabectedin -J9352 (A57298). Centers for Medicare & Medicaid Services, Inc. Updated on 09/19/2019 with effective date 09/26/2019. Accessed April 2020.
5. Palmetto GBA. Local Coverage Article (LCA): Billing and Coding: Chemotherapy (A56141). Centers for Medicare & Medicaid Services, Inc. Updated on 3/24/2020 with effective date 4/30/2020. Accessed April 2020.

Appendix 1 – Covered Diagnosis Codes

ICD-10	ICD-10 Description
C47.0	Malignant neoplasm of peripheral nerves of head, face and neck
C47.10	Malignant neoplasm of peripheral nerves of unspecified upper limb, including shoulder
C47.11	Malignant neoplasm of peripheral nerves of right upper limb, including shoulder
C47.12	Malignant neoplasm of peripheral nerves of left upper limb, including shoulder
C47.20	Malignant neoplasm of peripheral nerves of unspecified lower limb, including hip
C47.21	Malignant neoplasm of peripheral nerves of right lower limb, including hip
C47.22	Malignant neoplasm of peripheral nerves of left lower limb, including hip
C47.3	Malignant neoplasm of peripheral nerves of thorax
C47.4	Malignant neoplasm of peripheral nerves of abdomen
C47.5	Malignant neoplasm of peripheral nerves of pelvis
C47.6	Malignant neoplasm of peripheral nerves of trunk, unspecified
C47.8	Malignant neoplasm of overlapping sites of peripheral nerves and autonomic nervous system
C47.9	Malignant neoplasm of peripheral nerves and autonomic nervous system, unspecified

YONDELIS® (trabectedin) Prior Auth Criteria

Proprietary Information. Restricted Access – Do not disseminate or copy without approval.

©2020, Magellan Rx Management

ICD-10	ICD-10 Description
C48.0	Malignant neoplasm of retroperitoneum
C48.1	Malignant neoplasm of specified parts of peritoneum
C48.2	Malignant neoplasm of peritoneum, unspecified
C48.8	Malignant neoplasm of overlapping sites of retroperitoneum and peritoneum
C49.0	Malignant neoplasm of connective and soft tissue of head, face and neck
C49.10	Malignant neoplasm of connective and soft tissue of unspecified upper limb, including shoulder
C49.11	Malignant neoplasm of connective and soft tissue of right upper limb, including shoulder
C49.12	Malignant neoplasm of connective and soft tissue of left upper limb, including shoulder
C49.20	Malignant neoplasm of connective and soft tissue of unspecified lower limb, including hip
C49.21	Malignant neoplasm of connective and soft tissue of right lower limb, including hip
C49.22	Malignant neoplasm of connective and soft tissue of left lower limb, including hip
C49.3	Malignant neoplasm of connective and soft tissue of thorax
C49.4	Malignant neoplasm of connective and soft tissue of abdomen
C49.5	Malignant neoplasm of connective and soft tissue of pelvis
C49.6	Malignant neoplasm of connective and soft tissue of trunk, unspecified
C49.8	Malignant neoplasm of overlapping sites of connective and soft tissue
C49.9	Malignant neoplasm of connective and soft tissue, unspecified
C53.0	Malignant neoplasm of endocervix
C54.0	Malignant neoplasm of isthmus uteri
C54.1	Malignant neoplasm of endometrium
C54.2	Malignant neoplasm of myometrium
C54.3	Malignant neoplasm of fundus uteri
C54.8	Malignant neoplasm of overlapping sites of corpus uteri
C54.9	Malignant neoplasm of corpus uteri, unspecified
C55	Malignant neoplasm of uterus, part unspecified
C78.00	Secondary malignant neoplasm of unspecified lung
C78.01	Secondary malignant neoplasm of right lung
C78.02	Secondary malignant neoplasm of left lung
Z85.831	Personal history of malignant neoplasm of soft tissue

Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs) may exist and compliance with these policies is required where applicable. They can be found at: <http://www.cms.gov/medicare-coverage-database/search/advanced-search.aspx>. Additional indications may be covered at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD/LCA):

Jurisdiction(s): 15	NCD/LCD/LCA Document (s): A57298
https://www.cms.gov/medicare-coverage-database/search/document-id-search-results.aspx?DocID=A57298&bc=gAAAAAAAAAAAA&	

Jurisdiction(s): J&M	NCD/LCD/LCA Document (s): A56141
https://www.cms.gov/medicare-coverage-database/search/article-date-search.aspx?DocID=A56141&bc=gAAAAAAAAAAAA&	

Medicare Part B Administrative Contractor (MAC) Jurisdictions		
Jurisdiction	Applicable State/US Territory	Contractor
E (1)	CA, HI, NV, AS, GU, CNMI	Noridian Healthcare Solutions, LLC
F (2 & 3)	AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ	Noridian Healthcare Solutions, LLC
5	KS, NE, IA, MO	Wisconsin Physicians Service Insurance Corp (WPS)
6	MN, WI, IL	National Government Services, Inc. (NGS)
H (4 & 7)	LA, AR, MS, TX, OK, CO, NM	Novitas Solutions, Inc.
8	MI, IN	Wisconsin Physicians Service Insurance Corp (WPS)
N (9)	FL, PR, VI	First Coast Service Options, Inc.
J (10)	TN, GA, AL	Palmetto GBA, LLC
M (11)	NC, SC, WV, VA (excluding below)	Palmetto GBA, LLC
L (12)	DE, MD, PA, NJ, DC (includes Arlington & Fairfax counties and the city of Alexandria in VA)	Novitas Solutions, Inc.
K (13 & 14)	NY, CT, MA, RI, VT, ME, NH	National Government Services, Inc. (NGS)
15	KY, OH	CGS Administrators, LLC